

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HighTide Therapeutics, Inc.

君圣泰医药

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2511)

**HIGHTIDE THERAPEUTICS APPOINTS DR. FILIP
SURMONT AS CMO TO ADVANCE THE DEVELOPMENT OF
CARDIOVASCULAR-KIDNEY-METABOLIC (CKM)
SYNDROME PORTFOLIO**

This announcement is made by HighTide Therapeutics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business development of the Group.

The board of directors (the “**Board**”) of the Company announces the appointment of Dr. Filip Surmont as Chief Medical Officer. Dr. Surmont will oversee the Company’s global medical strategy, clinical development, and medical affairs, accelerating the clinical progress and value enhancement of HighTide’s core pipeline in the field of cardiovascular-kidney-metabolic (CKM) diseases.

Dr. Filip Surmont brings over 30 years of extensive experience in the healthcare and pharmaceutical industries, including 18 years in leadership positions at multinational pharmaceutical companies and 16 years of clinical practice. A globally recognized leader in the field of cardiovascular, metabolic, and renal diseases, he previously held senior medical leadership positions at Wyeth, Pfizer, and AstraZeneca. He has led medical affairs across diverse regions – including emerging markets, Latin America, Europe, the U.S., and China – successfully building high-performance teams and driving large-scale, guideline-level clinical practice transformations within complex global healthcare systems.

Throughout his distinguished career, Dr. Filip Surmont has contributed to the success of dapagliflozin as a blockbuster medication; led the “ACT on HF” project in China, enabling 200,000 heart failure patients to benefit from guideline-recommended standard of care; pioneered the Anti-Inflammatory Reliever (AIR) therapy strategy for asthma, impacting approximately 50 million patients worldwide and driving updates to international treatment guidelines. As a distinguished scientist, Dr. Filip Surmont has authored numerous peer-reviewed articles in elite medical journals, including *The Lancet Diabetes & Endocrinology* and *Journal of the American College of Cardiology*. In his early professional career, Dr. Filip Surmont has provided medical services for Olympic-level athletes. He holds an M.D. and a Master’s degree in Sports Medicine from Ghent University, Belgium.

By order of the Board
HighTide Therapeutics, Inc.
Dr. LIU Liping
Executive Director and Chief Executive Officer

Hong Kong, February 2, 2026

As at the date of this announcement, the Board comprises Dr. LIU Liping and Ms. YU Meng as executive Directors; Dr. ZHU Xun, Mr. MA Lixiong and Mr. JIANG Feng as non-executive Directors; and Mr. TAN Bo, Dr. LI Jin and Mr. HUNG Tak Wai as independent non-executive Directors.